Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
C4 Therapeutics (CCCC) has shared an update.
C4 Therapeutics, Inc. has initiated a strategic repricing of stock options to incentivize and retain key employees. The repricing impacts certain underwater stock options under the 2020 Plan, adjusting the exercise price to align with past IPO and high trading values. Senior leadership team members’ options are now priced at $19.00 per share, while others are set at $11.88. This move, designed to motivate without diluting stock or increasing cash outlay, comes with a stipulation that any termination or exercise within a year returns the exercise price to its original amount, preserving the company’s financial interests.
Learn more about CCCC stock on TipRanks’ Stock Analysis page.
